Evidence map›Paper›PMID 40183879›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025

Practice patterns in the diagnosis and management of chemotherapy-induced peripheral neuropathy in adolescents and young adults with cancer: a survey of oncologists.

Jennifer A Belsky, L Lee Dupuis, Lillian Sung, Allie Carter, Audrey Leisinger, Etan Orgel, Susan K Parsons, Michael Roth

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jennifer A BelskyDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, USA. Jbelsky@iu.edu.
L Lee DupuisDepartment of Pharmacy, Leslie Dan Faculty of Pharmacy, Research Institute, the Hospital for Sick Children, University of Toronto, Toronto, Canada.
Lillian SungDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.
Allie CarterDepartment of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, USA.
Audrey LeisingerDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, USA.
Etan OrgelCancer and Blood Disease Institute, Children's Hospital los Angeles, Los Angeles, USA.
Susan K ParsonsInstitute for Clinical Research and Health Policy Studies, Tufts Medical Center, Reid R. Sacco AYA Cancer Program, Boston, USA.
Michael RothMD Anderson Cancer Center, University of Texas, Austin, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeChemotherapy-induced peripheral neuropathy (CIPN) affects > 78% of oncology patients and causes detrimental side effects. There may be practice heterogenicity in CIPN management amongst oncologists treating pediatric, adolescent young adult (AYA), and adult patients with cancer. We sought to evaluate the practice patterns of oncologists regarding their management of CIPN in AYAs with cancer.

methodsA survey was developed and sent to pediatric and medical oncologists from across the United States. Scenarios included an 18-year-old receiving vincristine (VCR) with mild neuropathy (Scenario 1) and moderate/severe neuropathy (Scenario 2). Respondents were asked how they would manage each patient. Differences between pediatric and medical oncologists' management were assessed.

resultsA total of 179 responses were submitted by 132 (73.7%) pediatric, 44 (24.6%) medical oncologists, and 3 (1.6%) oncologists who care for both pediatric and adult patients. Over half of respondents for Scenario 1 would refer the patient to physical therapy (PT) (56.8%), 38.1% would prescribe a pharmacologic agent, and 27.8% would dose reduce/omit vincristine. For Scenario 2, most (81.8%) would dose reduce/omit vincristine, 69.3% would refer for PT, and 44.9% would start a pharmacologic agent. On multivariable analyses, medical oncologists were more likely to dose reduce/omit vincristine for Scenario 1 (OR, 7.68; 95% CI, 3.24-18.22) and Scenario 2 (OR, 5.52; 95% CI, 1.37-22.18, and less likely to refer to PT for Scenario 1 (OR, 0.12; 95% CI, 0.05-0.31) and Scenario 2 (OR, 0.18; 95% CI, 0.08-0.41).

conclusionOur survey suggests a broad spectrum of CIPN management in AYAs with cancer. The heterogenicity in practices and significant differences between pediatric and medical oncologists underscores an urgent need to better understand the source of heterogeneity in CIPN management practices and barriers to evidence-based care delivery.

Indexed as

Antineoplastic AgentsNeoplasmsOncologistsPeripheral Nervous System DiseasesPractice Patterns, Physicians'AdolescentAdultFemaleHumansMalePhysical Therapy ModalitiesSurveys and QuestionnairesUnited StatesVincristineYoung AdultAntineoplastic AgentsVincristineAdolescent young adultPediatric oncologyPeripheral neuropathySupportive care

Identifiers

PMID40183879
PMCPMC11971165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.